drugset
drugset / Trial / NCT03659305

Pharmacokinetic Equivalence and Safety Study of RPH-001 and Avastin®

NCT03659305 ↗

Phase 1 Completed 80 enrolled R-Pharm Almedis · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to confirm pharmacokinetic equivalence and compare clinical safety profile of RPH-001 and Avastin®.

Timeline

Start
2018-07-10
Primary completion
2019-01-26
Completion
2019-01-26

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bevacizumab Monoclonal antibody 5 mg/kg Intravenous
Subject RPH-001 Monoclonal antibody 5 mg/kg Intravenous

Indications

No indication recorded.